Last reviewed · How we verify

NCT04921722

Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies

Status unknown Phase 4 Last updated 15 March 2024
What this trial tests

Phase 4 trial testing Percutaneous sirolimus in Kaposiform Hemangioendothelioma in 75 participants. Status unknown.

Timeline
22 October 2021
Primary endpoint
1 November 2025
1 November 2025

Quick facts

Lead sponsorChildren's Hospital of Fudan University
PhasePhase 4
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment75
Start date22 October 2021
Primary completion1 November 2025
Estimated completion1 November 2025
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Children's Hospital of Fudan University

Who can join

Adults 0 to 18, any sex, with Kaposiform Hemangioendothelioma or Tufted Angioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study, we investigate the safety and efficacy of topical sirolimus in the treatment of superficial complicated vascular anomolies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Children's Hospital of Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04921722.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing